HR 3541, the "See the Board Act," creates a federal grant program to provide free eye care services to students in public elementary and secondary schools. The program, administered by the Secretary of Health and Human Services, awards grants to nonprofit organizations to purchase mobile eye care equipment and cover operational costs like staff, personal protective equipment, and optical services. These grants fund mobile clinics that bring vision screenings, comprehensive exams, and glasses directly to schools, targeting students attending public K-12 schools as defined under the Elementary and Secondary Education Act. The bill authorizes funding for fiscal years 2026 through 2031 to support this initiative.
The Black Vulture Relief Act of 2025 allows livestock producers and their employees to remove or kill black vultures that are harming or likely to harm livestock, but prohibits using poison for this purpose. It requires these individuals to submit an annual report to the U.S. Fish and Wildlife Service about vultures taken, using a simple form developed by the agency within 180 days of the bill’s enactment. The reporting form must be no more complicated than similar forms under the Migratory Bird Treaty Act. This bill directly affects livestock operations facing vulture-related losses while maintaining federal bird protections outside these specific circumstances.
This bill amends SEC reporting rules for investment companies (like mutual funds) by allowing them to exclude fees related to investments in business development companies (BDCs) from their "acquired fund fees and expenses" calculations. It directly affects investment companies filing registration statements with the SEC, simplifying their fee disclosures. BDCs are a specific type of investment vehicle that often supports small businesses, but this bill does not change BDC operations or directly provide new capital access for small businesses. The change only modifies how investment companies report certain fees in their registration documents.
This bill requires Medicare Advantage plans to implement electronic prior authorization systems by 2028 and report detailed transparency data starting in 2027. Plans must publicly disclose approval/denial rates, average processing times (including for appeals), technology use, and other metrics for covered medical services. It mandates 24-hour response standards for expedited requests and routinely approved services, with data collection to analyze access patterns and potential disparities in rural/low-income communities. These changes directly affect Medicare Advantage plans, providers, and seniors enrolled in these plans by standardizing and increasing visibility into prior authorization processes.
This bill amends U.S. immigration law to make certain nonimmigrant visa applicants inadmissible if their primary purpose for entering the U.S. is to give birth and automatically grant citizenship to their child. It specifically targets individuals seeking temporary visas (like tourist visas) primarily to obtain U.S. citizenship for their child through birth in the U.S., barring their admission. The bill includes a key exception: it does not apply to those seeking legitimate medical treatment related to childbirth if citizenship for the child is not the main reason for entry. The policy change would directly affect noncitizens attempting to enter the U.S. on temporary visas for the sole purpose of birthright citizenship.
The Strong Communities Act of 2025 creates a new federal grant program to fund law enforcement training for officers and recruits. Local police departments and sheriff's offices can receive grants to send officers to training programs at eligible colleges or police departments, with the requirement that officers serve at least 4 years in their local community after training. To qualify, officers must live within specific distances (7 or 20 miles) of their long-term residence (5+ years) and provide proof of employment. The program requires annual reports to Congress detailing grant recipients, training participants, and retention rates.
This bill reauthorizes the PROTECT Our Children Act of 2008 with updated requirements. It mandates a National Strategy for child exploitation prevention to be reviewed every four years (instead of every two), requiring detailed analyses of trends, resource needs, and ICAC task force performance. The bill modifies ICAC task force operations to include prioritizing victim identification, expands coordination with tribal/military agencies, and adds limited liability protections for task forces regarding investigative decisions. It increases annual funding for the program from $70 million (2026) to $90 million (2028), directly affecting federal agencies (DOJ, FBI, ICE), state/local law enforcement, and ICAC task forces nationwide.
This bill expands benefits for public safety officers (like police and firefighters) who develop certain cancers linked to their work. It creates a presumption that specific cancers - such as lung, bladder, or mesothelioma - were caused by job-related exposure to carcinogens, if the officer served at least 5 years, was diagnosed within 15 years of leaving active duty, and the cancer caused death or permanent disability. The list of covered cancers will be updated every 3 years based on medical evidence from agencies like the National Institute for Occupational Safety and Health. Claims must be filed within 3 years of the bill’s enactment, applying to cases involving deaths or disabilities occurring after January 1, 2020.
HR 3512, the Tackling Predatory Litigation Funding Act, imposes a new annual tax on funds received by third-party investors who finance lawsuits through litigation financing agreements. It directly affects investors (including foreign entities) who provide funding to plaintiffs or law firms in exchange for a share of settlement or judgment proceeds, excluding small agreements under $10,000 or standard loans. The tax equals the top individual income tax rate plus 3.8 percentage points, with 50% withheld from settlement payments by parties involved in the lawsuit. The law also clarifies that such funds cannot offset losses and excludes certain typical legal fee reimbursements from taxation. The provisions take effect for taxable years beginning after December 31, 2025.
This bill would allocate $200 million annually from 2026 through 2029 to expand access to diapers and incontinence supplies for low-income families. It specifically targets infants, toddlers, medically complex children, and low-income adults with disabilities who require diapers or incontinence products. The funding would be distributed through state social services programs to support free distribution of diapers, diapering supplies, and adult incontinence materials, while requiring states to track how funds are used through detailed reporting. The bill also makes medically necessary diapers and diapering supplies eligible for reimbursement through health savings accounts and flexible spending arrangements. This legislation aims to address what is termed "diaper need" by directly providing essential supplies to vulnerable populations.
Clinical Trial Modernization Act This bill authorizes a grant program and provides certain exemptions to support the participation of individuals in clinical trials. Specifically, the bill authorizes a grant program to support outreach, education, and recruitment efforts for clinical trials that may benefit certain underrepresented populations or communities in need, such as rural or tribal areas. The bill also exempts from anti-kickback laws for federal health care programs (1) remuneration that is offered to cover participants' expenses to participate in clinical trials, (2) the provision of free digital health technologies to support participation of underrepresented populations in clinical trials, and (3) payment for participants' cost-sharing obligations in relation to clinical trials. Finally, the bill exempts up to $2,000 in remuneration that is received for participating in a clinical trial from income tax.
HR 3520, the STAND Against Emerging Opioids Act, adds tianeptine and its similar compounds (including salts, isomers, and analogues) to Schedule III of the federal Controlled Substances Act. This change directly affects individuals who use, distribute, or manufacture tianeptine, placing it under federal regulation similar to other controlled substances. The bill amends the Controlled Substances Act to require federal oversight of tianeptine, effective 90 days after the bill's enactment. This policy change shifts tianeptine from unregulated status to a controlled substance category, impacting its legal availability and use.
